Nocturnal polyuria, a key contributing factor of nocturia in adults, is characterized by overproduction of urine at night. Changes in lifestyle and circadian rhythms, and conditions such as…
The treatment of newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) has evolved in recent years with the approval of hormonal agents such as Zytiga (Johnson & Johnson), Xtandi (…
The primary goal of glaucoma treatment is to reduce and control intraocular pressure. In the United States, the treatment armamentarium for open-angle glaucoma (OAG) has expanded in recent years…
2020 will be a turning point for the U.S. acute migraine market. Three novel therapies—Allergan’s Ubrelvy, Eli Lilly’s Reyvow, and Biohaven’s Nurtec ODT—entered the market in rapid…
Clarivate’s Epidemiology's coverage of heart failure (HF) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the diagnosed event…
Clarivate’s Epidemiology's coverage of heart failure (HF) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the diagnosed event…
Tumor necrosis factor-alpha (TNF-α) inhibitors (e.g., AbbVie’s Humira, Amgen’s Enbrel) and Janssen’s interleukin (IL)-12/23 inhibitor Stelara have been leading the U.S. psoriasis biologics…
MARKET OUTLOOK Systemic Lupus Erythematosus (SLE) is an autoimmune disease that affects multiple organ systems of the body. SLE symptoms range from general malaise to serious CNS and renal…
Metformin and sulfonylureas are the most heavily prescribed type 2 diabetes drugs and dominate the early lines of therapy, before disease progression requires insulin replacement. The emergence of…
Uterine fibroids are characterized by heavy menstrual bleeding (menorrhagia), pelvic pressure due to increased uterine bulk, abdominal and back pain, and fertility issues. Disease management may…
Biosimilars of erythropoiesis-stimulating agents (ESAs) entered the European market a decade ago, but the FDA did not approve the first ESA biosimilar—Retacrit—until June 2018; it launched in…
The poly ADP ribose polymerase (PARP) inhibitors, such as AstraZeneca’s Lynparza, GSK’s Zejula, and Clovis Oncology’s Rubraca, have revolutionized the therapeutic landscape of platinum-…
The poly ADP ribose polymerase (PARP) inhibitors, such as AstraZeneca’s Lynparza, GSK’s Zejula, and Clovis Oncology’s Rubraca, have revolutionized the therapeutic landscape of platinum-…
Giant cell arteritis (GCA) is an autoimmune disease marked by inflammation of blood vessels in the head and neck, leading to persistent headaches, flu-like symptoms, and risk of blindness. The most…
Primary, or essential, hypertension is defined as persistently elevated blood pressure without any identifiable cause. It is a major risk factor for various cardiovascular diseases (e.g., coronary…